Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Escalating Single IV Doses of Ocrelizumab in Moderate to Severe RA
NCT02720120Phase 2Terminated
- Sponsor
- Roche
- Start
- Oct 2005
- Primary completion
- Feb 2013
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 2 trial of ocrelizumab in rheumatoid arthritis (RA), sponsored by Roche. Started Oct 2005; status: terminated.
02
Drugs
ocrelizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02720120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02720120.